Drs. Armstrong, Wallis on AI Biomarkers and HRQoL for Localized Prostate Cancer, mCRPC

Andrew Armstrong, MD, MSc, Duke University School of Medicine, and Christopher Wallis, MD, PhD, University of Toronto, discuss the design and implications of an AI-derived digital pathology-based biomarker to predict benefit of long-term ADT with radiotherapy in men with localized high-risk prostate, as well as HRQoL for patients with mCRPC who received abiraterone plus olaparib in the PROpel trial.